Skip to main content
. 2021 Nov 16;297(6):101420. doi: 10.1016/j.jbc.2021.101420

Figure 4.

Figure 4

HER2/PD-L1 BsAb suppressed the proliferation of HER2+tumor cells.A, HER2/PD-L1 BsAb and trastuzumab, but not avelumab, could bind to SKBR3 cells. B, HER2/PD-L1 BsAb and trastuzumab, but not isotype control, suppressed SKBR3 cells proliferation in CCK-8 assay.